08:38 AM EDT, 07/23/2025 (MT Newswires) -- Solid Biosciences ( SLDB ) said Wednesday the US Food and Drug Administration has granted fast track designation for SGT-501, its investigational gene therapy for treating catecholaminergic polymorphic ventricular tachycardia, a heart condition.

The fast track designation is intended to speed up development and review of treatments for serious conditions with unmet medical needs, the company said.